Shares of Replimune have moved 3.8% today, and are now trading at a price of $25.96. In contrast, the S&P 500 index saw a 1.3% change and the Dow Industrial Average posted a 1.0% performance. Today's trading volume is 483,257 compared to the stock's average volume of 393,938.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Based in Woburn, United States the company has 206 full time employees and a market cap of $1,291,234,816.
The company is now trading -43.87% away from its average analyst target price of $46.25 per share. The 8 analysts following the stock have set target prices ranging from $34 to $60, and on average give Replimune a rating of strong buy.
Over the last year, REPL shares have gone down by -10.9%, which represents a difference of 4.8% when compared to the S&P 500. The stock's 52 week high is $30.89 per share and its 52 week low is $13.05. With negative earnings per share and negative cahs flows since 2019, Replimune may not have a strong enough business to reverse this trend.
| 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | |
|---|---|---|---|---|
| Earnings Per Share | n/a | n/a | $-1.75 | $-2.26 |
| EPS Growth | n/a | n/a | n/a | -29.14% |
| Free Cash Flow | $-27,978,000.0 | $-67,092,000.0 | $-63,781,000.0 | $-84,516,000.0 |
| FCF Growth | n/a | -139.8% | 4.94% | -32.51% |
